Measuring outcomes Emma Frew October 2012.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Introduction to Effectiveness, Patient Preferences and Utilities Patsi Sinnott, PT, PhD, MPH HERC Economics Course May 6, 2009.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
PHAR 310: Pharmacoeconomics
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Rescuing Clinical Trial Data For Economic Evaluation
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Long-Term Outcomes after Acute Stroke Treatment Larry B. Goldstein, M.D. Professor of Medicine (Neurology) Center for Cerebrovascular Disease Center for.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences
Table 1. Characteristics of generic HRQOL assessments in adult physical activity research Peter D. Hart et al. Systematic Review of Health-Related Quality.
General Introduction Some Notes. Definition of Measurement “Measurement consists of rules for assigning numbers to observable attributes so as to represent.
Professor David Parkin King’s College London
HEALTH ECONOMICS BASICS
Global burden of diseases
Lecture 15 Assoc. Prof. Sencer Ecer HEALTH ECONOMICS
Professor Nancy Devlin Director of Research OHE
M. Dakoutrou, V. Gerovasili, G. Sidiras, I. Patsaki, A. Kouvarakos, S
Quality of Life Assessment
Patient Baseline Assessment
How useful is a reminder system in collection of follow-up quality of life data in clinical trials? Dr Shona Fielding.
A Primer on Health Economics and Cost-Effectiveness
Effect of framing of death on health state values obtained from DCEs
The valuation of disease-specific questionnaires for QALY analysis
Health care decision making
Sergio Bautista-Arredondo National Institute of Public Health Mexico
Is healthcare any good for patients
Measuring benefits Morris et al (2012) Ch
Assessing value for money: principles, methods and issues
Health Economics for Prescribers
Student Champions Learning about NICE
How to Measure Quality of Life
Presentation transcript:

Measuring outcomes Emma Frew October 2012

Learning objectives By the end of the session students should be able to Explain how different methods of economic evaluation may be appropriate in different circumstances; Describe the methods involved in obtaining quality of life values for use in QALYs; Calculate QALYs gained, given data on life expectancy and health status; Demonstrate familiarity with EQ-5D, the NICE-recommended instrument for calculating QALYs; Start to appraise the value of QALYs, given the theoretical, methodological and ethical challenges that they pose.

Outline Choice of evaluation type QoL measures Calculating QALYs using EQ-5D Methods for obtaining QoL values Brief appraisal of QALY methodology

Outcomes in economic evaluation Economic evaluation involves comparative analysis of two or more interventions in terms of both costs AND benefits Outcome measurement therefore important What sorts of outcomes do we want?

Depends on what we want to compare… When only want to compare alternatives within a condition: CEA - measures benefits in terms of some standard clinical outcome or effectiveness, e.g. change in blood pressure. When want to compare across conditions: CEA – life years gained – but what about other impacts? CUA - impacts on both the quality and quantity of life, e.g. QALYs CBA - measures both the resource costs and health benefits in monetary terms

Valuing outcome for CEA Must choose ONE single outcome Proxy outcome (not ideal)? E.g. cancers detected E.g. change in blood pressure Life years gained?

Problems of multiple outcomes Cost Effect on life expectancy Effect on Quality of life A Low No change Large improvement B High Modest improvement Modest improvement

Valuing outcome Must choose ONE single outcome Proxy outcome (not ideal)? E.g. cancers detected E.g. change in blood pressure Life years gained? Money difficult in practice… Quality-adjusted life-year (QALY)?

What are QALYs? Combines length and quality of life into single unit Weights used to adjust survival data Involves valuing health states on a cardinal (interval or ratio) scale with maximum value of 1 (perfect health) and value of 0 equal to death Used to weight life years QALY = (length of life) x (QoL)

QALYs

Calculating QALYs Prognosis without treatment Prognosis with treatment (0.7x1) + (0.6x2) + (0.4x1) + (0.3x1) + (0.2x1) + (0.1x2) = 3.0 Prognosis with treatment (0.5x1) + (0.6x1) + (0.7x1) + (0.8x1) + (0.9x4) = 6.2 Total gain in QALYs 6.2 – 3.0 = 3.2

LY – Life Years Life years can be obtained from life tables Average life expectancy For example: Life expectancy at birth by health and local authorities in the United Kingdom 1991-1993 to 2002-2004, including revised results for England and Wales 1991-1993 to 2000-2002 accessed via http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8841 Some evaluations require information about survival linked to the intervention Results are rolling averages, produced by aggregating deaths and population estimates for each 3-year period.

QA –Quality Adjustment What sort of quality adjustment is required? What do we mean by quality of life?

Specific versus generic measures Specific measures Aim for a narrow assessment of health related to a particular condition Can only be used for that particular condition Examples: Dermatology Life Quality Index, Beck Depression Inventory, Arthritis Impact Measurement Scale (AIMS) Are more sensitive to the particular condition under investigation Cannot be used to compare across conditions GENERALLY NOT HELPFUL FOR ESTIMATING QALYs

Specific versus generic measures Aim for a broad assessment of health related QoL Can be used across all different conditions Examples: Nottingham Health Profile, SF36, COOP WONCA charts, EQ-5D, HUI Can be insensitive to some problems OR can be very long as they try to look comprehensively across the whole of health

Profile versus index measures Profile measures Aim to provide a profile of an individual’s health Questions can be summed into sub-categories Profiles can be clustered by disease or condition group Examples: Sickness Impact Profile, Nottingham Health Profile, SF-36 GENERALLY NOT HELPFUL FOR ESTIMATING QALYs

Profile versus index measures Examples of profile measures Nottingham Health Profile 13 dimensions, 45 items Physical mobility, pain, sleep, energy, social isolation, emotional reactions, employment, social life, household work, sex life, home life, holidays, interests, hobbies SF-36 8 dimensions, 36 items Physical functioning, vitality, social functioning, bodily pain, general mental health, general health perceptions, role limitations – physical, role limitations - emotional

Profile versus index measures Aim to provide a single index value representing an individual’s health Aims to be comprehensive but trade off between number of dimensions and ability to obtain an index value Incorporates social preferences / weights so that the index numbers are “meaningful” Examples: EQ-5D, SF-6D, 15D, HUI

Profile versus index measures Examples of index measures EQ-5D 5 dimensions, 3 items Mobility, self care, usual activities, pain / discomfort, anxiety / depression HUI2 7 dimensions, 7 items Sensation, mobility, emotion, self care, cognition, pain, fertility

Estimating QALYs using an index measure EQ-5D (EuroQol) Health Utilities Index (HUI II and HUI III) Quality of Well-Being Scale (QWB) 15D SF-6D (derived from SF-36)

EQ-5D Five dimensions: Each with three levels PLUS thermometer (VAS) Mobility Self care Usual activities Pain/discomfort Anxiety/depression Each with three levels PLUS thermometer (VAS)

Examples of EQ-5D questions Mobility I have no problems in walking about I have some problems in walking about I am confined to bed Pain/Discomfort I have no pain or discomfort I have moderate pain or discomfort I have extreme pain or discomfort

Valuing health QALYs gained = QALYs with treatment - QALYs without treatment = treatment (QoL x LE) - non-treatment (QoL x LE) = (1.0 x10) - (0.743 x 10) = 10 - 7.43 = 2.57 QALYs gained QoL with treatment: 11111 (value 1.0) for 10 years QoL without treatment: 21212 (value 0.743) for 10 years

Important aspects Importance of value judgements Who will make judgements? What will be the dimensions? Numbers (values) to be assigned Should a QALY be a QALY be a QALY? i.e. should the valuation of a QALY be the same, irrespective of who is involved? Weights must have interval properties Scale must be anchored consistently at death and good health

Measuring outcomes: exercise 1